• Prescribing Information
  • Medication Guide
  • Patient Site
  • Dosing
    Learn about dosing and administration
    Efficacy
    Learn about CHANTIX efficacy
    Safety
    Review the full safety information for CHANTIX
    Quit Approaches
    Patients can set a quit date after 1 week, in up to 1 month, or gradually, in up to 12 weeks 1

    Flexibility in Setting a Quit Date

    Please be advised that CHANTIX is currently out of stock. For medical questions on CHANTIX and for supply updates, please contact Pfizer Medical Information at 1-800-438-1985.

    CHANTIX offers patients flexibility in setting a quit date, whether it’s after 1 week, up to 1 month, or gradually, in up to 12 weeks1

    Fixed Quit approach1

    For patients who want to put their cigarettes down after 1 week1

    With this approach, patients:

    • Set a target quit date for 1 week after starting treatment
    • Take CHANTIX for 12 weeks

    See efficacy data.

    Flexible Quit approach1

    For patients who want to put their cigarettes down in up to 1 month1

    With this approach, patients:

    • Set a target quit date between days 8 and 35 of treatment
    • Take CHANTIX for 12 weeks

    See efficacy data.

    Gradual Quit approach1

    Patients unsure or unwilling to put their cigarettes down abruptly can quit gradually, in up to 12 weeks1

    With this approach, patients:

    • Begin CHANTIX dosing and reduce smoking by 50% from baseline during the first 4 weeks
      • During the next 4 weeks, reduce smoking by an additional 50%
      • Continue reducing with the goal of reaching complete abstinence by 12 weeks
    • Take CHANTIX for a total of 24 weeks

    See efficacy data.

    Patients can continue to smoke when they first start CHANTIX, regardless of when they set a quit date.1​​​​​​​


    ​​​​​​​How CHANTIX is believed to work​​​​​​​

    CHANTIX works in a way that is believed to help break the reward cycle of nicotine1,3

    The efficacy of CHANTIX in smoking cessation is believed to be the result of varenicline's activity at the α4β2 subtype of the nicotine receptor, where its binding produces agonist activity while simultaneously preventing nicotine from binding to these receptors.1​​​​​​​

    Based on animal models and in vitro studies. For illustrative purpose only.

    Dosing & Administration

    Learn about dosing and administration

    How to prescribe

    References
    1. CHANTIX [package insert]. New York, NY: Pfizer Inc.
    2. Tonstad S, Tønnesen P, Hajek P, Williams KE, Billing CB, Reeves KR; Varenicline Phase 3 Study Group. Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. JAMA. 2006;296(1):64-71.
    3. Coe JW, Brooks PR, Vetelino MG, et al. Varenicline: an α4β2 nicotinic receptor partial agonist for smoking cessation. J Med Chem. 2005;48(10):3474-3477.

    INDICATION AND LIMITATIONS OF USE

    CHANTIX is indicated as an aid to smoking cessation treatment in adults.

    CHANTIX is contraindicated in patients with a history of serious hypersensitivity or skin reactions to CHANTIX.

    Postmarketing reports of serious or clinically significant neuropsychiatric adverse events have been reported in patients treated with CHANTIX. These included changes in mood (including depression and mania), psychosis, hallucinations, paranoia, delusions, homicidal ideation, aggression, hostility, agitation, anxiety, and panic, as well as suicidal ideation, suicide attempt, and completed suicide. Observe patients attempting to quit smoking with CHANTIX for the occurrence of such symptoms and instruct them to discontinue CHANTIX and contact a healthcare provider immediately if they experience such adverse events.

    During clinical trials and the postmarketing experience, there have been reports of seizures in patients treated with CHANTIX, with or without a history of seizures. CHANTIX should be used cautiously in patients with a history of seizures or other factors that can lower the seizure threshold. Instruct patients to discontinue CHANTIX, and contact a healthcare provider immediately if they experience a seizure while on treatment.

    There have been postmarketing reports of patients experiencing increased intoxicating effects of alcohol while taking CHANTIX, including unusual and sometimes aggressive behavior directed to oneself or to others and often accompanied by amnesia. Advise patients to reduce the amount of alcohol they consume while taking CHANTIX until they know whether CHANTIX affects their tolerance for alcohol.

    Patients with underlying cardiovascular (CV) disease may be at increased risk of CV events; however, these concerns must be balanced with the health benefits of smoking cessation. Instruct patients to notify their healthcare providers of new or worsening CV symptoms and to seek immediate medical attention if they experience signs and symptoms of myocardial infarction (MI) or stroke.

    Cases of somnambulism have been reported in patients taking CHANTIX. Some cases described harmful behavior to self, others, or property. Instruct patients to discontinue CHANTIX and notify their healthcare provider if they experience somnambulism.

    Patients should be informed that there have been reports of serious skin reactions, such as Stevens Johnson Syndrome and Erythema Multiforme and of angioedema, with swelling of the face, mouth, and neck that can lead to life-threatening respiratory compromise. Patients should be instructed to discontinue CHANTIX and immediately seek medical care if they experience these symptoms or at the first sign of rash with mucosal lesions or any other signs of hypersensitivity.

    The most common adverse reactions include nausea (30%), abnormal dreams, constipation, flatulence, and vomiting. Patients should be informed that they may experience vivid, unusual, or strange dreams during treatment with CHANTIX. Patients should be advised to use caution driving or operating machinery or engaging in other potentially hazardous activities until they know how CHANTIX may affect them.

    Safety and efficacy of CHANTIX in combination with other smoking cessation drug therapies have not been studied. Dosage adjustment with CHANTIX is recommended in patients with severe renal impairment or in patients undergoing hemodialysis.

    Smoking cessation, with or without treatment with CHANTIX, may alter the pharmacokinetics or pharmacodynamics of some drugs, such as theophylline, warfarin, and insulin. Dosage adjustment for these drugs may be necessary.

    CHANTIX is indicated as an aid to smoking cessation treatment in adults.